The Paul Ehrlich Institute approved a Hospital Exemption for Northwest Biotherapeutics Inc.'s (Nasdaq: NWBO) DCVax-L to treat glioma brain tumors and the German reimbursement authority approved reimbursement from the Sickness Funds for DCVax-L treatments. Shares of the biotechnology firm leaped $1.79 to close at $7.85.
Northwest Biotherapeutics Receives German Approvals
March 10, 2014 at 17:31 PM EDT
